| Name | Title | Contact Details |
|---|---|---|
Sarah O'Brien |
Chief People Officer | Profile |
Andrew Drechsler |
Chief Financial Officer | Profile |
Thierry Chauche |
Chief Financial Officer | Profile |
Jane Sterling |
Director, Human Resources | Profile |
Sarah O`Brien |
Chief People Officer | Profile |
Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we are also developing next-generation TIL products and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, Lion is committed to elevating hope and treatment standards for patients, while creating exceptional value for its shareholders.
Arteriocyte, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Center For Innovation Inc is a Butte, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bio Analytical Research Corporation is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The KPC Group is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.